 |
 Video: What is a Stock Split?
|
|
|
| Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s primary product candidate, roflumilast cream, has the potential to provide symptomatic improvement in psoriasis patients similar to the combination of a high potency steroid and calcipotriene, a tolerability profile, the ability to be used chronically, and little to none of the application site reactions associated with various existing topical treatments. Co. is also developing a foam formulation of topical roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis. According to our Arcutis Biotherapeutics stock split history records, Arcutis Biotherapeutics has had 0 splits. | |
|
Arcutis Biotherapeutics (ARQT) has 0 splits in our Arcutis Biotherapeutics stock split history database.
Looking at the Arcutis Biotherapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arcutis Biotherapeutics shares, starting with a $10,000 purchase of ARQT, presented on a split-history-adjusted basis factoring in the complete Arcutis Biotherapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/03/2020 |
|
| End date: |
05/01/2024 |
|
| Start price/share: |
$25.13 |
|
| End price/share: |
$8.84 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-64.82% |
|
| Average Annual Total Return: |
-21.83% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,518.62 |
|
| Years: |
4.24 |
|
|
|
|
|
